FOR IMMEDIATE RELEASE
October 14, 2008

Media Contact: Alicia Moran, 703-739-2424 x 110

Sequella to Present Major Developments at International Infectious Disease Meeting

New data on lead antitubercular compounds SQ109, SQ641
Identification of anti-fungal compounds
TB drug synergy data with Tibotec TMC207

Rockville, Maryland -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products to treat infectious diseases of epidemic potential announced that it will present 5 posters at the joint meeting of the Interscience Conference on Anti-Microbial Agents and Chemotherapy (ICAAC) and Infectious Disease Society of America (IDSA) in Washington, DC, on October 25-28, 2008.

Demonstrating leadership and strength in infectious disease research and tuberculosis (TB) drug development, Sequella scientists will present results from in vitro synergy studies with Tibotec lead TB drug candidate, TMC207, and Sequella lead TB drug candidate, SQ109. Sequella will also present pre-clinical research studies on new translocase-1 (TL-1) inhibitor SQ641 and data on new compounds demonstrating anti-fungal activity.

Sequella will present the following posters:

- October 26, 2008, 11:15 AM / SESSION# 103 / PRESENTATION# F1-1163: In vitro Activities of Capuramycin (CM) Analogues against Nontuberculous Mycobacteria (NTM)
- October 26, 2008, 11:15 AM / SESSION# 103 / PRESENTATION# F1-1162: Activity of SQ641, a Capuramycin (CM) Analog, in Murine Models of Tuberculosis (TB)
- October 26, 2008, 11:15 AM / SESSION# 105 / PRESENTATION# F1-1186: Identification of Several Compound Series with Antifungal Activity
- October 28, 2008, 11:15 AM / SESSION# 279 / PRESENTATION# C1-3848: The New Antitubercular Drugs SQ109 and TMC207 Act Synergistically In Vitro to Kill M. tuberculosis
- October 28, 2008, 11:15 AM / SESSION# 279 / PRESENTATION# C1-3851: Enhancement of Intracellular Activity of Capuramycin (CM) Analogue SQ641 against M. tuberculosis (MTB)

“The joint ICAAC and IDSA meeting is an important opportunity for Sequella to share new information about our very substantial progress on two promising drug candidates that could change the way TB is treated in the future,” said Sequella CEO, Dr. Carol A. Nacy. “These compounds have the potential to provide early and prolonged bacterial
clearance during the intensive phase of TB therapy and could shorten and improve TB treatment. In addition, we've broadened our focus to infectious diseases outside of TB, and we will present new data on drugs that are effective against non-TB mycobacteria (NTM) and on new classes of compounds with activity against important fungal agents that cause systemic disease in hospitalized patients, *Candida albicans*, *Candida glabrata*, and *Aspergillus fumigatus*.”

### # # #

**About SQ109**
The company’s lead TB drug candidate, SQ109, is completing Phase I clinical trials and is a new diamine antibiotic that could replace one or more of the current first-line anti-tuberculosis drugs to shorten or simplify therapy. SQ109 was granted U.S. FDA Fast Track and FDA/EMEA Orphan Drug Designation designation in 2007.

**About SQ641**
SQ641 is the lead drug candidate from a 7000-compound library of semisynthetic TL-1 inhibitors developed as potential treatments for TB or bacterial pneumonia (*Streptococcus pneumoniae*). TL-1 is an enzyme required for cell wall synthesis in all bacteria, including *Mycobacteria*. Sequella licensed the compound library from Daiichi-Sankyo (November 2004). Daiichi-Sankyo identified the compound class and performed extensive research and preliminary preclinical development on several drug leads. Sequella has exclusive rights to the series of TL-1 inhibitors for the treatment of TB and all other indications for nearly every worldwide market.

**About Sequella**
Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms, and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

**Forward-Looking Statement**
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.